Combination therapy of interferon and nucleotide/nucleoside analogues for chronic hepatitis B

Journal of Viral Hepatitis

Volumn 21, Issue 12, 2014, Pages 825-834

  Wong, G L H ^a,b   Wong, V W S ^a,b   Chan, H L Y ^a,b  

^a CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

^b CHINESE UNIVERSITY OF HONG KONG   (Hong Kong)

Author keywords

adefovir dipivoxil; entecavir; lamivudine; peginterferon; telbivudine; tenofovir

Indexed keywords

ADEFOVIR; ADEFOVIR DIPIVOXIL; ENTECAVIR; HEPATITIS B(E) ANTIGEN; INTERFERON; LAMIVUDINE; PEGINTERFERON; PEGINTERFERON ALPHA2A; PEGINTERFERON ALPHA2B; RNA DIRECTED DNA POLYMERASE INHIBITOR; TELBIVUDINE; TENOFOVIR; TENOFOVIR DISOPROXIL; ANTIVIRUS AGENT; NUCLEOSIDE; NUCLEOTIDE;

ANTIVIRAL THERAPY; CHRONIC HEPATITIS; DRUG MECHANISM; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; IMMUNOTHERAPY; META ANALYSIS (TOPIC); MULTICENTER STUDY (TOPIC); NONHUMAN; PHASE 4 CLINICAL TRIAL (TOPIC); RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; DRUG COMBINATION; HEPATITIS B, CHRONIC; PROCEDURES; TREATMENT OUTCOME;

ANTIVIRAL AGENTS; DRUG THERAPY, COMBINATION; HEPATITIS B, CHRONIC; HUMANS; INTERFERONS; NUCLEOSIDES; NUCLEOTIDES; TREATMENT OUTCOME;

EID: 84910606683     PISSN: 13520504     EISSN: 13652893     Source Type: Journal    
DOI: 10.1111/jvh.12341     Document Type: Review

References (80)

1. Wong DK, Cheung AM, O'Rourke K, Naylor CD, Detsky AS, Heathcote J,. Effect of alpha-interferon treatment in patients with hepatitis B e antigen-positive chronic hepatitis B. A meta-analysis. Ann Intern Med 1993; 119 (4): 312-323.
2. Lai CL, Chien RN, Leung NW, et al,. A one-year trial of lamivudine for chronic hepatitis B. Asia Hepatitis Lamivudine Study Group. N Engl J Med 1998; 339 (2): 61-68.
3. Lo AO, Wong GL,. Current developments in nucleoside/nucleotide analogues for hepatitis B. Expert Rev Gastroenterol Hepatol 2014; 8 (6): 607-622.
4. Lau GK, Piratvisuth T, Luo KX, et al,. Peginterferon Alfa-2a, lamivudine, and the combination for HBeAg-positive chronic hepatitis B. N Engl J Med 2005; 352 (26): 2682-2695.
5. Lok AS, McMahon BJ,. Chronic hepatitis B: update 2009. Hepatology 2009; 50 (3): 661-622.
6. European Association for the Study of the Liver. EASL clinical practice guidelines: management of chronic hepatitis B virus infection. J Hepatol 2012; 57 (1): 167-185.
7. Liaw YF, Kao JH, Piratvisuth T, et al,. Asian-Pacific consensus statement on the management of chronic hepatitis B: a 2012 update. Hepatol Int 2012; 6: 531-561.
8. Sung JJ, Tsoi KK, Wong VW, Li KC, Chan HL,. Meta-analysis: treatment of hepatitis B infection reduces risk of hepatocellular carcinoma. Aliment Pharmacol Ther 2008; 28 (9): 1067-1077.
9. Wong GL, Yiu KK, Wong VW, Tsoi KK, Chan HL,. Meta-analysis: reduction in hepatic events following interferon-alfa therapy of chronic hepatitis B. Aliment Pharmacol Ther 2010; 32 (9): 1059-1068.
10. Wong GL, Chan HL, Mak CW, et al,. Entecavir treatment reduces hepatic events and deaths in chronic hepatitis B patients with liver cirrhosis. Hepatology 2013; 58 (5): 1537-1547.
11. Rabe B, Vlachou A, Pante N, Helenius A, Kann M,. Nuclear import of hepatitis B virus capsids and release of the viral genome. Proc Natl Acad Sci USA 2003; 100 (17): 9849-9854.
12. Gerelsaikhan T, Tavis JE, Bruss V,. Hepatitis B virus nucleocapsid envelopment does not occur without genomic DNA synthesis. J Virol 1996; 70 (7): 4269-4274.
13. Bruss V, Lu X, Thomssen R, Gerlich WH,. Post-translational alterations in transmembrane topology of the hepatitis B virus large envelope protein. EMBO J 1994; 13 (10): 2273-2279.
14. Isaacs A,. Interferon. Adv Virus Res 1963; 10: 1-38.
15. Larrubia JR, Benito-Martinez S, Miquel-Plaza J, Sanz-de-Villalobos E, Gonzalez-Mateos F, Parra T,. Cytokines-their pathogenic and therapeutic role in chronic viral hepatitis. Rev Esp Enferm Dig 2009; 101 (5): 343-351.
16. Wong GL, Chan HL,. Predictors of treatment response in chronic hepatitis B. Drugs 2009; 69 (16): 2167-2177.
17. Buster EH, Schalm SW, Janssen HL,. Peginterferon for the treatment of chronic hepatitis B in the era of nucleos(t)ide analogues. Best Pract Res Clin Gastroenterol 2008; 22 (6): 1093-1108.
18. Lok AS, Lai CL, Wu PC, Leung EK,. Long-term follow-up in a randomised controlled trial of recombinant alpha 2-interferon in Chinese patients with chronic hepatitis B infection. Lancet 1988; 2 (8606): 298-302.
19. Niederau C, Heintges T, Lange S, et al,. Long-term follow-up of HBeAg-positive patients treated with interferon alfa for chronic hepatitis B. N Engl J Med 1996; 334 (22): 1422-1427.
20. van Zonneveld M, Honkoop P, Hansen BE, et al,. Long-term follow-up of alpha-interferon treatment of patients with chronic hepatitis B. Hepatology 2004; 39 (3): 804-810.
21. Marcellin P, Lau GK, Bonino F, et al,. Peginterferon alfa-2a alone, lamivudine alone, and the two in combination in patients with HBeAg-negative chronic hepatitis B. N Engl J Med 2004; 351 (12): 1206-1217.
22. Chan HL, Leung NW, Hui AY, et al,. A randomized, controlled trial of combination therapy for chronic hepatitis B: comparing pegylated interferon-alpha2b and lamivudine with lamivudine alone. Ann Intern Med 2005; 142 (4): 240-250.
23. Janssen HL, van Zonneveld M, Senturk H, et al,. Pegylated interferon alfa-2b alone or in combination with lamivudine for HBeAg-positive chronic hepatitis B: a randomised trial. Lancet 2005; 365 (9454): 123-129.
24. Wong VW, Chan HL,. Chronic hepatitis B: a treatment update. Semin Liver Dis 2013; 33 (2): 122-129.
25. Urban S, Schulze A, Dandri M, Petersen J,. The replication cycle of hepatitis B virus. J Hepatol 2010; 52 (2): 282-284.
26. Wong GL, Chan HL, Chan HY, et al,. Accuracy of risk scores for patients with chronic hepatitis B receiving entecavir treatment. Gastroenterology 2013; 144 (5): 933-944.
27. Chan HL, Thompson A, Martinot-Peignoux M, et al,. Hepatitis B surface antigen quantification: why and how to use it in 2011-a core group report. J Hepatol 2011; 55 (5): 1121-1131.
28. Lok AS, Lai CL, Leung N, et al,. Long-term safety of lamivudine treatment in patients with chronic hepatitis B. Gastroenterology 2003; 125 (6): 1714-1722.
29. Allen MI, Deslauriers M, Andrews CW, et al,. Identification and characterization of mutations in hepatitis B virus resistant to lamivudine. Lamivudine Clinical Investigation Group. Hepatology 1998; 27 (6): 1670-1677.
30. Libbrecht E, Doutreloigne J, Van De Velde H, et al,. Evolution of primary and compensatory lamivudine resistance mutations in chronic hepatitis B virus-infected patients during long-term lamivudine treatment, assessed by a line probe assay. J Clin Microbiol 2007; 45 (12): 3935-3941.
31. Tan J, Degertekin B, Wong SN, Husain M, Oberhelman K, Lok AS,. Tenofovir monotherapy is effective in hepatitis B patients with antiviral treatment failure to adefovir in the absence of adefovir-resistant mutations. J Hepatol 2008; 48 (3): 391-398.
32. Shaw T, Bartholomeusz A, Locarnini S,. HBV drug resistance: mechanisms, detection and interpretation. J Hepatol 2006; 44 (3): 593-606.
33. Chisari FV, Ferrari C,. Hepatitis B virus immunopathogenesis. Annu Rev Immunol 1995; 13: 29-60.
34. Boni C, Penna A, Ogg GS, et al,. Lamivudine treatment can overcome cytotoxic T-cell hyporesponsiveness in chronic hepatitis B: new perspectives for immune therapy. Hepatology 2001; 33 (4): 963-971.
35. Enomoto M, Nishiguchi S, Tamori A, et al,. Entecavir and interferon-alpha sequential therapy in Japanese patients with hepatitis B e antigen-positive chronic hepatitis B. J Gastroenterol 2013; 48 (3): 397-404.
36. Mutimer D, Naoumov N, Honkoop P, et al,. Combination alpha-interferon and lamivudine therapy for alpha-interferon-resistant chronic hepatitis B infection: results of a pilot study. J Hepatol 1998; 28 (6): 923-929.
37. Barbaro G, Zechini F, Pellicelli AM, et al,. Long-term efficacy of interferon alpha-2b and lamivudine in combination compared to lamivudine monotherapy in patients with chronic hepatitis B. An Italian multicenter, randomized trial. J Hepatol 2001; 35 (3): 406-411.
38. Tatulli I, Francavilla R, Rizzo GL, et al,. Lamivudine and alpha-interferon in combination long term for precore mutant chronic hepatitis B. J Hepatol 2001; 35 (6): 805-810.
39. van Zonneveld M, Zondervan PE, Cakaloglu Y, et al,. Peg-interferon improves liver histology in patients with HBeAg-positive chronic hepatitis B: no additional benefit of combination with lamivudine. Liver Int 2006; 26 (4): 399-405.
40. Marcellin P, Avila C, Wursthorn K, et al,. Telbivudine (LdT) plus peg-interferon (PEGIFN) in HBeAg-positive chronic hepatitis B-very potent antiviral efficacy but risk of peripheral neuropathy (PN). J Hepatol 2010; 52 (Suppl. 1): S6-S7.
41. Enomoto M, Tamori A, Nishiguchi S, Kawada N,. Combination therapy with a nucleos(t)ide analogue and interferon for chronic hepatitis B: simultaneous or sequential. J Gastroenterol 2013; 48 (9): 999-1005.
42. Chan HL, Wong VW, Tse AM, et al,. Serum hepatitis B surface antigen quantitation can reflect hepatitis B virus in the liver and predict treatment response. Clin Gastroenterol Hepatol 2007; 5 (12): 1462-1468.
43. Rijckborst V, Hansen BE, Ferenci P, et al,. Validation of a stopping rule at week 12 using HBsAg and HBV DNA for HBeAg-negative patients treated with peginterferon alfa-2a. J Hepatol 2012; 56 (5): 1006-1011.
44. Chan HL, Wong GL, Chim AM, Chan HY, Chu SH, Wong VW,. Prediction of off-treatment response to lamivudine by serum hepatitis B surface antigen quantification in hepatitis B e antigen-negative patients. Antivir Ther 2011; 16 (8): 1249-1257.
45. Matsumoto A, Tanaka E, Suzuki Y, et al,. Combination of hepatitis B viral antigens and DNA for prediction of relapse after discontinuation of nucleos(t)ide analogs in patients with chronic hepatitis B. Hepatol Res 2012; 42 (2): 139-149.
46. Kittner JM, Sprinzl MF, Grambihler A, et al,. Adding pegylated interferon to a current nucleos(t)ide therapy leads to HBsAg seroconversion in a subgroup of patients with chronic hepatitis B. J Clin Virol 2012; 54 (1): 93-95.
47. Marques AR, Lau DT, McKenzie R, Straus SE, Hoofnagle JH,. Combination therapy with famciclovir and interferon-alpha for the treatment of chronic hepatitis B. J Infect Dis 1998; 178 (5): 1483-1487.
48. Yalcin K, Degertekin H, Yildiz F, Celik Y,. Comparison of 12-month courses of interferon-alpha-2b-lamivudine combination therapy and interferon-alpha-2b monotherapy among patients with untreated chronic hepatitis B. Clin Infect Dis 2003; 36 (12): 1516-1522.
49. Jang MK, Chung YH, Choi MH, et al,. Combination of alpha-interferon with lamivudine reduces viral breakthrough during long-term therapy. J Gastroenterol Hepatol 2004; 19 (12): 1363-1368.
50. Ayaz C, Celen MK, Colak H, Hosoglu S, Geyik MF,. Comparison of lamivudine and alpha-interferon combination with alpha-interferon alone in the treatment of HBeAg-positive chronic hepatitis B. Indian J Gastroenterol 2006; 25 (2): 71-73.
51. Yuki N, Nagaoka T, Nukui K, Omura M, Hikiji K, Kato M,. Adding interferon to lamivudine enhances the early virologic response and reversion of the precore mutation in difficult-to-treat HBV infection. J Gastroenterol 2008; 43 (6): 457-463.
52. Schalm SW, Heathcote J, Cianciara J, et al,. Lamivudine and alpha interferon combination treatment of patients with chronic hepatitis B infection: a randomised trial. Gut 2000; 46 (4): 562-568.
53. Sangfelt P, Uhnoo I, Hollander A, Lindh G, Weiland O,. Lamivudine and famciclovir combination therapy with or without addition of interferon-alpha-2b for HBeAg-positive chronic hepatitis B: a pilot study. Scand J Infect Dis 2002; 34 (7): 505-511.
54. Schiff ER, Dienstag JL, Karayalcin S, et al,. Lamivudine and 24 weeks of lamivudine/interferon combination therapy for hepatitis B e antigen-positive chronic hepatitis B in interferon nonresponders. J Hepatol 2003; 38 (6): 818-826.
55. Hasan F, al-Khaldi J, Asker H, et al,. Treatment of chronic hepatitis B with the sequential administration of interferon and lamivudine. Hepatogastroenterology 2003; 50 (54): 2040-2042.
56. Sarin SK, Kumar M, Kumar R, et al,. Higher efficacy of sequential therapy with interferon-alpha and lamivudine combination compared to lamivudine monotherapy in HBeAg positive chronic hepatitis B patients. Am J Gastroenterol 2005; 100 (11): 2463-2471.
57. Xu JH, Yu YY, Si CW, et al,. [Comparison of lamivudine or interferon monotherapy and sequential therapy in chronic hepatitis B: a random controlled trial]. Beijing Da Xue Xue Bao 2010; 42 (6): 739-745.
58. Jaboli MF, Fabbri C, Liva S, et al,. Long-term alpha interferon and lamivudine combination therapy in non-responder patients with anti-HBe-positive chronic hepatitis B: results of an open, controlled trial. World J Gastroenterol 2003; 9 (7): 1491-1495.
59. Karabay O, Tamer A, Tahtaci M, Vardi S, Celebi H,. Effectiveness of lamivudine and interferon-alpha combination therapy versus interferon-alpha monotherapy for the treatment of HBeAg-negative chronic hepatitis B patients: a randomized clinical trial. J Microbiol Immunol Infect 2005; 38 (4): 262-266.
60. Santantonio T, Niro GA, Sinisi E, et al,. Lamivudine/interferon combination therapy in anti-HBe positive chronic hepatitis B patients: a controlled pilot study. J Hepatol 2002; 36 (6): 799-804.
61. Schiefke I, Klecker C, Maier M, et al,. Sequential combination therapy of HBe antigen-negative/virus-DNA-positive chronic hepatitis B with famciclovir or lamivudine and interferon-alpha-2a. Liver Int 2004; 24 (2): 98-104.
62. Scotto G, Palumbo E, Fazio V, Cibelli DC, Saracino A, Angarano G,. Efficacy and tolerability of lamivudine alone versus lamivudine plus alpha-interferon for treatment of chronic active hepatitis B in patients with a precore-mutant variant. Infez Med 2006; 14 (3): 145-151.
63. Shi M, Wang RS, Zhang H, et al,. Sequential treatment with lamivudine and interferon-alpha monotherapies in hepatitis B e antigen-negative Chinese patients and its suppression of lamivudine-resistant mutations. J Antimicrob Chemother 2006; 58 (5): 1031-1035.
64. Yang SS, Hsu CT, Hu JT, Lai YC, Wu CH,. Lamivudine does not increase the efficacy of interferon in the treatment of mutant type chronic viral hepatitis B. World J Gastroenterol 2002; 8 (5): 868-871.
65. Sarin SK, Sood A, Kumar M, et al,. Effect of lowering HBV DNA levels by initial antiviral therapy before adding immunomodulator on treatment of chronic hepatitis B. Am J Gastroenterol 2007; 102 (1): 96-104.
66. Chan HL, Wong VW, Chim AM, et al,. Virological response to different combination regimes of peginterferon alpha-2b and lamivudine in hepatitis B e antigen positive chronic hepatitis B. Antivir Ther 2007; 12 (5): 815-823.
67. Cao ZH, Ma LN, Zhang HW, Liu YL, Chen XY,. Extended treatment with peginterferon alpha-2a in combination with lamivudine or adefovir for 96 weeks yields high rates of HBeAg and HBsAg seroconversion. J Dig Dis 2013; 14 (8): 446-450.
68. Zeng W, Yuan J, Liu YX, et al,. [Efficacy of Peg-interferon alpha-2a combinated with entecavir on HBeAg positive chronic hepatitis B patients with high serum hepatitis B viral loads]. Zhonghua Shi Yan He Lin Chuang Bing Du Xue Za Zhi 2013; 27 (2): 115-118.
69. Su WW, Hsu CW, Lee CM, et al,. Combination therapy with peginterferon alfa-2a and a nucleos(t)ide analogue for HBeAg-positive chronic hepatitis B patients: results of a large, randomised, multicentre, double-blind, placebo-controlled study. J Hepatol 2014; 60 (1): S47.
70. Huang Z, Zhao Z, Zheng Y, et al,. Efficacy of sequential use of telbivudine in hepatitis B e antigen-positive chronic hepatitis B patients with partial responses to pegylated interferon: a pilot study. J Viral Hepat 2013; 20 (Suppl. 1): 52-57.
71. Marcellin P, Gane E, Buti M, et al,. Regression of cirrhosis during treatment with tenofovir disoproxil fumarate for chronic hepatitis B: a 5-year open-label follow-up study. Lancet 2013; 381 (9865): 468-475.
72. Kaymakoglu S, Oguz D, Gur G, et al,. Pegylated interferon Alfa-2b monotherapy and pegylated interferon Alfa-2b plus lamivudine combination therapy for patients with hepatitis B virus E antigen-negative chronic hepatitis B. Antimicrob Agents Chemother 2007; 51 (8): 3020-3022.
73. Piccolo P, Lenci I, Demelia L, et al,. A randomized controlled trial of pegylated interferon-alpha2a plus adefovir dipivoxil for hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2009; 14 (8): 1165-1174.
74. Reijnders JG, Perquin MJ, Zhang N, Hansen BE, Janssen HL,. Nucleos(t)ide analogues only induce temporary hepatitis B e antigen seroconversion in most patients with chronic hepatitis B. Gastroenterology 2010; 139 (2): 491-498.
75. Liang Y, Jiang J, Su M, et al,. Predictors of relapse in chronic hepatitis B after discontinuation of anti-viral therapy. Aliment Pharmacol Ther 2011; 34 (3): 344-352.
76. Ning Q, Han M, Sun Y, et al,. Switching from entecavir to PegIFN alfa-2a in patients with HBeAg-positive chronic hepatitis B: a randomised open-label trial (OSST trial). J Hepatol 2014; 61 (4): 777-784.
77. Wursthorn K, Lutgehetmann M, Dandri M, et al,. Peginterferon alpha-2b plus adefovir induce strong cccDNA decline and HBsAg reduction in patients with chronic hepatitis B. Hepatology 2006; 44 (3): 675-684.
78. Wang YX, Zheng SM, Zhang Y, et al,. Sustained efficacy of adefovir add-on therapy in chronic hepatitis B patient with a poor virological response to peginterferon alfa. Scand J Gastroenterol 2013; 48 (2): 213-217.
79. Huang Z, Deng H, Zhao Q, et al,. Peginterferon-alpha2a combined with response-guided short-term lamivudine improves response rate in hepatitis B e antigen-positive hepatitis B patients: a pilot study. Eur J Gastroenterol Hepatol 2013; 25 (10): 1165-1169.
80. Piccolo P, Lenci I, di Paolo D, et al,. A randomized controlled trial of sequential pegylated interferon-alpha and telbivudine or vice versa for 48 weeks in hepatitis B e antigen-negative chronic hepatitis B. Antivir Ther 2013; 18 (1): 57-64.